Summit Therapeutics Inc (SMMT) fair value: what the stock is really worth
As of Nov 20, 2026: fair value (intrinsic value) of Summit Therapeutics Inc stock $5.87, price $9.95, that is 41.0% below the price, quality 33 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently applies, it draws on revenue and assets compared with similar companies. Updated daily.
🚩Pivotal trial missed survival significance for FDA filing🚩Dependence on Akeso licence and milestones🚩Competition from Keytruda and other bispecifics plus biosimilars🚩Sustained zero revenue and large losses
Watch Summit Therapeutics Inc for free: once a week we email you where price and fair value stand.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 22, 2026.
How to read this chart
60‑month range $0.68 – $36.70 · fair‑value band $4.40 – $7.33 · the $9.95 price screens above the $5.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 22, 2026.
Follow Summit Therapeutics in your weekly email
Every Wednesday you see whether Summit Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.
Show moreShow less
Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa.
The company was founded in 2003 and is headquartered in Miami, Florida.
Stock analysis
Summit Therapeutics Inc (SMMT) currently trades at $9.95, while our estimate is $5.87, 41% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $4.40 (bear) to $7.33 (bull), the price of $9.95 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Summit Therapeutics Inc reported revenue of £0 in FY2025 versus £1.8M in FY2021. Reported net income was −£1.1B in FY2025.
Key figures
Market cap $8.0B Mid · EPS (TTM) $-1.06 · Return on equity −220% · Return on assets (EBIT) −132% (5-year average) · Free cash flow −$240M · Net cash £152M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).
What moves the price
The share trades about 62% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −4% fair-value upside, at −41%, SMMT screens richer than that median.
Fair Value
Bear$4.40Fair Value $5.87Bull$7.33
Price $9.95 · Downside -41.0%
Estimate. None of our valuation models currently applies to this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Quality Score breakdown
Overall quality33/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability0
How much profit the company makes from its sales and capital
Quality Growth25
Are margins and returns getting better?
Cashflow0
Do the profits arrive as real cash?
Financial strength97
Debt, balance sheet and risk of trouble
Investment48
Does it invest with discipline instead of growing at any price?
Low Volatility50
How calm the share price moves, does not count
Price momentum17
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, 3 officers or directors bought shares worth $103.6M, most recently on Jun 12, 2026. Buying cluster
BuyRobert W DugganCo-Chief Executive Officer, Director, 10% owner2× since Jun 4, 2026: 3,910,000 shares, avg. $13.16$51.4MJun 12, 2026
BuyMahkam ZanganehCo-Chief Executive Officer, Director, 10% owner2× since Jun 4, 2026: 3,910,000 shares, avg. $13.16$51.4MJun 12, 2026
BuyManmeet Singh SoniCOO and CFO, Director50,000 shares at $14.45$722,250Jun 4, 2026
Plus 6 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−67.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−76.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−47.2%
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.5%
’10
’11
’12
’13
’14
’15
’16
’17
’18
’19
’21
’22
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−182.3% (2017) → −10,225.4% (2022)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (100 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Very negative
AI conclusion: The narrow moat pre-revenue biotech draws main strength from its large strategic equity investment and expanded ivonescimab program, yet its main weak point is minimal evidence of durable advantage amid sustained losses.
Main risk: Summit depends on its licence from Akeso for ivonescimab, facing potential regulatory and commercial milestones plus royalties that could strain cash flow if commercial sales fall short.
Summit has lined up a large strategic equity investment and expanded its ivonescimab program into additional tumor types, yet the lead FDA filing rests on overall survival data that missed statistical significance in the pivotal trial. Our models currently see the stock as overvalued. Will the growing clinical network and partner support carry the company through if regulators insist on a clear survival benefit?
Compare Summit Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 854 stocks
Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score33 · Below median
Fair Value upside−41.0% · Bottom 25%
Profitability
Return on assets−193.7% · Bottom 25%
Balance sheet
Debt / equity0.21× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B16.27× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 32
PAST (return on equity)0· sector 0
HEALTH (low debt)90· sector 96
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Summit Therapeutics Inc (SMMT) overvalued or undervalued?
As of Nov 22, 2026, our estimate of fair value is $5.87 versus a price of $9.95, about 41% lower (overvalued).
What is the fair value of SMMT?
Our estimate for Summit Therapeutics Inc is $5.87 (as of Nov 22, 2026), built from audited fundamentals. The current price: $9.95.
What is the quality score of SMMT?
Summit Therapeutics Inc has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Summit Therapeutics Inc (SMMT)?
We do not set a price target; the yardstick is our estimate of $5.87 (as of Nov 22, 2026). Cautious scenario $4.40, optimistic scenario $7.33. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently applies, not an analyst target.
What is the Summit Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $5.87, about 41% lower versus a price of $9.95 (overvalued). Cautious scenario $4.40, optimistic scenario $7.33. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Summit Therapeutics Inc (SMMT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Summit Therapeutics Inc it is $5.87 per share (as of Nov 22, 2026), against a price of $9.95.
Is Summit Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 22, 2026, SMMT trades above its calculated fair value: price $9.95, fair value $5.87, a gap of about −41% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SMMT?
No. The price is what the market pays today ($9.95); the fair value is what the company's own numbers justify ($5.87). For Summit Therapeutics Inc the two are $4.08 per share apart. That gap is exactly why we show both numbers side by side.
How much is Summit Therapeutics Inc worth?
The market values Summit Therapeutics Inc at about $8.0B (market capitalisation, as of Nov 22, 2026). Per share that is $9.95; our models calculate a fair value of $5.87 per share.
What do the bullish and bearish scenarios say about SMMT?
Our models span a range for Summit Therapeutics Inc: cautious scenario $4.40, base $5.87, optimistic $7.33 per share (as of Nov 22, 2026, price $9.95). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Summit Therapeutics Inc (SMMT)?
Balance-sheet figures for Summit Therapeutics Inc (as of Nov 22, 2026): return on equity −220.0%, debt of 0.21 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is SMMT from its 52-week high?
Summit Therapeutics Inc trades at $9.95, about 62% below its 52-week high of $26.38 and at the low of $9.95 (as of Nov 20, 2026). Distance from the high says nothing about value: that is what the fair value of $5.87 is for.
Which stocks are comparable to Summit Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Summit Therapeutics Inc stock attractive at the current price?
The data as of Nov 22, 2026: price $9.95, calculated fair value $5.87 (−41%), Quality Score 33/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 10.1% above its aggregate fair value. Summit Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Summit Therapeutics Inc (SMMT)?
The closing price on Nov 20, 2026 was $9.95. Our estimate is $5.87, about 41% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Summit Therapeutics Inc right now?
The price sits above even our optimistic bull case ($7.33). The favourable scenario is already priced in. Weak quality (33/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Summit Therapeutics Inc
How large is the market capitalisation of Summit Therapeutics Inc (SMMT)?
The market capitalisation of Summit Therapeutics Inc is $8.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Summit Therapeutics Inc (SMMT)?
Earnings per share at Summit Therapeutics Inc are $-1.06. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Summit Therapeutics Inc (SMMT)?
The return on equity (ROE) of Summit Therapeutics Inc is −220% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Summit Therapeutics Inc (SMMT)?
On an EBIT basis the return on assets of Summit Therapeutics Inc is −132% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Summit Therapeutics Inc (SMMT) generate?
The free cash flow of Summit Therapeutics Inc is −$240M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Summit Therapeutics Inc (SMMT) hold?
Summit Therapeutics Inc holds more cash than debt, £152M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Summit Therapeutics Inc in the live analysis
One click puts Summit Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.